SMA Awareness Month is a time for the entire SMA community to come together and raise awareness to improve outcomes for patients across Canada.
Pioneers in Neuroscience
BYOOVIZ™, first LUCENTIS® biosimilar, now available in Canada to treat debilitating retinal disorders
Canadian-made video game designed to help maintain abilities and quality of life for children with rare, degenerative neuromuscular disease
CADTH Ruling on SPINRAZA™ (nusinersen) Extinguishes Hope for Adults Needing Treatment for Spinal Muscular Atrophy (SMA)
Update on Regulatory Submission for Aducanumab in Canada
Draft CADTH Recommendation for SPINRAZATM (nusinersen) Fails Adults in Need of Treatment for Spinal Muscular Atrophy (SMA)
Health Canada Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (Ranibizumab)
Biogen Canada Welcomes Eric Tse as New General Manager in New Toronto Head Office
Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of SPINRAZA™ (nusinersen) in Patients Previously Treated with Evrysdi® (risdiplam)
Biogen Canada receives Top 50 Best Workplaces™ in Canada and Best Workplaces™ for Women
Biogen Canada recognized as a Great Place to Work® and one of the 2020 Best Workplaces™ in Healthcare
Biogen Canada investment in newborn screening study underlines commitment to research in spinal muscular atrophy (SMA)
Further Together in SMA
COVID-19 Update
Stepping up to support Canadian communities during the COVID-19 pandemic
The impact of the COVID-19 pandemic is being felt around the world and by so many. More than ever, our communities need us and are counting on our support. This is the rationale behind the Biogen Foundation $10M global commitment to address the immediate needs of communities and hospital systems.
COVID-19 Update
TO PATIENTS, HEALTHCARE PROVIDERS, PARTNERS, AND OUR COMMUNITY
As the novel coronavirus (COVID-19) outbreak evolves in Canada and around the world, the health and safety of all those who are impacted in any way is our utmost concern.
Biogen Canada Inc.
3250 Bloor Street West
East Tower, Suite 1200
Toronto ON, M8X 2X9
General Information
Phone: +1 866 359 2502 or +1 416 234 7999
Fax: +1 416 234 7849
Email: CanadaGeneral.Mailbox@biogen.com
About Biogen
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases.
Working at Biogen Canada
We work together to bring life-changing therapies to patients every day. Start here to find the fulfilling career opportunity that’s right for you.
Explore disease areas:
Learn more about Biogen on our global site